Surface Oncology, Inc.
(NASDAQ : SURF)

( )
SURF After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.23%207.410.0%$1713.99m
BIIBBiogen, Inc. 2.40%406.141.7%$1308.00m
SNSSSunesis Pharmaceuticals, Inc. 9.01%12.950.7%$905.25m
NVAXNovavax, Inc. -0.94%207.7179.8%$703.35m
AMGNAmgen, Inc. -0.65%241.191.3%$607.30m
BNTXBioNTech SE -7.53%220.580.0%$521.84m
GILDGilead Sciences, Inc. 0.13%68.151.0%$461.62m
VRTXVertex Pharmaceuticals, Inc. 0.92%194.801.9%$449.28m
ILMNIllumina, Inc. -0.23%452.143.5%$372.79m
REGNRegeneron Pharmaceuticals, Inc. 0.61%528.752.7%$364.34m
ALXNAlexion Pharmaceuticals, Inc. 0.00%181.652.0%$341.36m
OCGNOcugen, Inc. -3.31%6.130.0%$262.85m
EXASEXACT Sciences Corp. 2.56%125.0118.1%$192.21m
BNGOBionano Genomics, Inc. 3.17%7.820.0%$186.15m
ONTXOnconova Therapeutics, Inc. 6.93%7.561.8%$181.22m

Company Profile

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.